Vera Therapeutics (VERA) Net Cash Flow (2020 - 2026)

Vera Therapeutics (VERA) has 7 years of Net Cash Flow data on file, last reported at -$240.4 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow fell 540.04% year-over-year to -$240.4 million; the trailing twelve-month figure through Mar 2026 stood at $59.3 million (up 522.84% YoY), and the FY2025 full-year result was $262.1 million, up 458.03% from the prior year.
• Net Cash Flow for Q1 2026 stood at -$240.4 million, down from $297.0 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $297.0 million in Q4 2025 and bottomed at -$240.4 million in Q1 2026.
• The 5-year median for Net Cash Flow is $2.2 million (2024), against an average of $2.0 million.
• The widest annual swing landed in 2022, when Net Cash Flow soared 867.22%; it then tumbled 540.04% in 2026.
• A 5-year view of Net Cash Flow shows it stood at $13.0 million in 2022, then jumped by 40.48% to $18.2 million in 2023, then soared by 258.5% to $65.4 million in 2024, then soared by 354.12% to $297.0 million in 2025, then tumbled by 180.95% to -$240.4 million in 2026.
• The last three Net Cash Flow figures came in at -$240.4 million (Q1 2026), $297.0 million (Q4 2025), and $8.7 million (Q3 2025), per Business Quant data.

Peer Comparison